Caplin Point Laboratories (NSE:CAPLIPOINT) Cyclically Adjusted PB Ratio: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
91 GF Score
Price ₹2,560.80
GF Value ₹2,205.57
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Caplin Point Laboratories  (NSE:CAPLIPOINT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Caplin Point Laboratories Cyclically Adjusted PB Ratio Related Terms


Caplin Point Laboratories Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Caplin Point Laboratories's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caplin Point Laboratories Cyclically Adjusted PB Ratio Chart

Caplin Point Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.20 6.47 10.74 12.63 7.02

Caplin Point Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 10.81 0.00 7.02 0.00

NSE:CAPLIPOINT vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Cyclically Adjusted PB Ratio falls into.


NSE:CAPLIPOINT
91GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caplin Point Laboratories Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Caplin Point Laboratories's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Caplin Point Laboratories's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Caplin Point Laboratories Quarterly Data

Book Value per Share CPI Adj_Book
201609 21.740 105.961 34.337
201612 0.000 105.196 0.000
201703 29.740 105.196 47.314
201706 0.000 107.109 0.000
201709 38.082 109.021 58.459
201712 0.000 109.404 0.000
201803 48.123 109.786 73.358
201806 0.000 111.317 0.000
201809 57.563 115.142 83.667
201812 0.000 115.142 0.000
201903 78.935 118.202 111.761
201906 0.000 120.880 0.000
201909 102.638 123.175 139.454
201912 0.000 126.235 0.000
202003 115.454 124.705 154.942
202006 0.000 127.000 0.000
202009 139.582 130.118 179.530
202012 0.000 130.889 0.000
202103 156.767 131.771 199.105
202106 0.000 134.084 0.000
202109 175.489 135.847 216.194
202112 0.000 138.161 0.000
202203 195.798 138.822 236.045
202206 0.000 142.347 0.000
202209 222.129 144.661 256.979
202212 0.000 145.763 0.000
202303 247.748 146.865 282.317
202306 0.000 150.280 0.000
202309 273.055 151.492 301.651
202312 0.000 152.924 0.000
202403 304.931 153.035 333.470
202406 0.000 155.789 0.000
202409 334.491 157.882 354.565
202412 0.000 158.323 0.000
202503 375.005 157.552 398.344
202506 0.000 159.755 0.000
202509 415.638 162.289 428.618
202512 0.000 163.281 0.000
202603 471.823 164.272 480.683
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,560.80 is trading 16.1% above its estimated GF Value™ of ₹2,205.57. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹2,205.57 vs. price of ₹2,560.80 (16.1% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
91GF Score

Get the complete analysis for NSE:CAPLIPOINT

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,560.80
Price
₹2,205.57
GF Value